Phase 3 N=39 Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy
Glomerulonephritis, Membranous
Primary: Percentage of Complete Remission — 4; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=9 Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)
Lupus Membranous Nephropathy
Primary: Percent Change in Urine Protein From Baseline (Day 1) to Week 16 — -2.8; -51.2 percent change
Phase 2 N=14 A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy
Glomerulonephritis, Membranous
Primary: Change From Baseline in Proteinuria Levels at Week 28 — 0.7552 Ratio
Phase 4 N=40 Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis
Glomerulonephritis, Membranous
Primary: Number of Patient Who Gained Remission From the Nephrotic Syndrome — 8; 8 Participants — p=0.7
Phase 3 N=144 A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis
Lupus Nephritis
Primary: Percentage of Participants Who Achieved a Complete Renal Response (CRR), a Partial Renal Response (PRR), or no Renal Response (NRR) at Week 52 — 26.4; 30.6; 30.6; 15.3…
Phase 3 N=130 MEmbranous Nephropathy Trial Of Rituximab
Idiopathic Membranous Nephropathy
Primary: Remission Status — 39; 13 Participants — p=0.001
Phase 2 N=125 A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)
Lupus Nephritis
Primary: Percentage of Participants Who Achieve Protocol Defined Complete Renal Response (CRR) at Week 52 — 22; 14 Participants — p=0.1145
Phase 3 N=370 A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.
Lupus Nephritis
Primary: Induction Phase: Number of Patients Showing Treatment Response — 98; 104; 87; 81 participants — p=0.478
Phase 2 N=43 Rituximab and Belimumab for Lupus Nephritis
Lupus Nephritis
Primary: Percentage of Participants With At Least One Grade 3 or Higher Infectious Adverse Event By Week 24, Week 48 and Week 96 — 9.1; 4.8; 22.7; 9.5 percentage of participants…
Phase 3 N=448 Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
Lupus Nephritis
Primary: Double-blind Period: Percentage of Participants With Primary Efficacy Renal Response (PERR) at Week 104 — 32.3; 43.0 Percentage of participants — p=0.0311
Phase 2 N=137 Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis
Lupus Nephritis · Lupus Erythematosus, Systemic
Primary: Number of Participants With Complete Response — 22; 21 participants — p=0.85
Phase 2 N=121 Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis
Lupus Nephritis
Primary: Percentage of Patients With Complete Renal Response (CRR) at Week 52 — 38.32; 44.95; 44.56; 48.33 Percentage of Participants — p=0.7271
Phase 2 N=46 A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis
Lupus Nephritis
Primary: Number of Participants With Adverse Events (AEs) — 14; 15; 15 participants
Phase 4 N=5 Adrenocorticotropic Hormone in Membranous Nephropathy
Membranous Nephropathy
Primary: Change in Proteinuria — 4.56; 1.36 ratio
Phase 2 N=81 Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare
Lupus Nephritis
Primary: Number of Patients With Complete Remission — 8; 8; 34; 31 Participants
Phase 2 N=21 Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis
Lupus Nephritis
Primary: Complete and Partial Response Rate — 55 Percentage of participants
Phase 4 N=60 Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
Proteinuria · Idiopathic Membranous Nephropathy
Primary: Percentage of Participants With Complete or Partial Remission in Proteinuria at 24 Weeks — 1; 5; 2; 0 Participants
Phase 4 N=84 Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
SLE · Lupus Nephritis · SGLT2 Inhibitors
Primary: Effect of Dapagliflozin Compared to Placebo on Renal Function After One Year — 128; 114; 115.7; 100.3 mL/min/1.73 m²
Phase 2 N=99 Prospective Study of Rapamycin for the Treatment of SLE
Systemic Lupus Erythematosus (SLE)
Primary: Reduction of the Disease Activity as Measured by SLEDAI and BILAG Scores. — 10.2; 28.4 score on a scale
N/A N=193 Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and Quality of Life (QoL) of Participants With Lupus Nephritis
Systemic Lupus Erythematosus
Primary: Number of Participants Categorized by Demographic Characteristics — 143; 50; 88; 3 Participants
Phase 2 N=31 Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)
Glomerulonephritis, Membranous · antiPLA2R Positive
Primary: Number of Participants With Adverse Events — 15; 12 Participants
Phase 2 N=9 Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Primary: Relapse-free Complete Clinical Response — 54 Months
Phase 2 N=57 Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.
Lupus Nephritis
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 33; 18; 6; 3 Participants
Phase 2 N=69 An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis
Lupus Nephritis
Primary: Percentage of Patients With Complete Renal Response (CRR) and Without Any Renal Flares — 51.83; 48.15; 59.49; 57.51 Percentage of participants — p=0.7957
Phase 2 N=15 Permeability Factor in Focal Segmental Glomerulosclerosis
Focal Segmental Glomerulosclerosis
Primary: Reduction in Proteinuria in Recurrent FSGS Following Renal Transplant With Plasma Exchange and Cyclophosphamide. — 0; 0; 0.5; 0.25 proportion of participants with…
Phase 2 N=147 Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis
Lupus Nephritis
Primary: Change From Baseline in 24-hour Urine Protein to Creatinine Ratio (UPCR) — 0.326; 0.285; 0.305; 0.296 milligram/milligram (mg/mg) — p=0.9052
Phase 2 N=76 ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 23; 24; 2; 2 Participants
Phase 2 N=7 Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
FSGS · MCD · Focal Segmental Glomerulosclerosis
Primary: Change in Urine MCP1/Cr Levels — 5.57; 2.89 ng/mg
Phase 2 N=46 Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
IgA Nephropathy
Primary: MCP-Mod Estimates of the Ratio to Baseline of Urine Protein to Creatinine Ratio (UPCR) (g/Mol) - Parts 1 and 2 at Day 90 — 0.85; 0.80; 0.76; 0.69 Ratio to baseline…
Phase 1 N=52 Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis
Lupus Erythematosus · Lupus Nephritis
Primary: Number of Treatment Emergent Adverse Events — 0; 17; 2; 4 Participants